Global Opioid Use Disorder Market Overview:
Global Opioid Use Disorder Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2025 as the base year.
Global Opioid Use Disorder Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Opioid Use Disorder involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Opioid Use Disorder Market:
The Opioid Use Disorder Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Opioid Use Disorder Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Opioid Use Disorder Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Opioid Use Disorder market has been segmented into:
Buprenorphine
Methadone
Naltrexone
and Others
By Application, Opioid Use Disorder market has been segmented into:
Oral and Parenteral
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Opioid Use Disorder market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Opioid Use Disorder market.
Top Key Players Covered in Opioid Use Disorder market are:
Indivior PLC
Alkermes
Orexo AB
Titan Pharmaceuticals
Inc
Teva Pharmaceutical Industries Ltd.
Mallinckrodt Pharmaceuticals
BioDelivery Sciences International Inc.
Viatris Inc.
Hikma Pharmaceuticals PLC
Camurus AB
Sun Pharmaceutical Industries Ltd.
Amneal Pharmaceuticals LLC.
Purdue Pharma LP
Alvogen
Faran Shimi Pharmaceutical
Novartis AG
Emplicure AB
MODASA Pharmaceuticals Pvt. Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Opioid Use Disorder Market by Type
4.1 Opioid Use Disorder Market Snapshot and Growth Engine
4.2 Opioid Use Disorder Market Overview
4.3 Buprenorphine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Buprenorphine: Geographic Segmentation Analysis
4.4 Methadone
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Methadone: Geographic Segmentation Analysis
4.5 Naltrexone
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Naltrexone: Geographic Segmentation Analysis
4.6 and Others
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 and Others: Geographic Segmentation Analysis
Chapter 5: Opioid Use Disorder Market by Application
5.1 Opioid Use Disorder Market Snapshot and Growth Engine
5.2 Opioid Use Disorder Market Overview
5.3 Oral and Parenteral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral and Parenteral: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Opioid Use Disorder Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 INDIVIOR PLC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 ALKERMES
6.4 OREXO AB
6.5 TITAN PHARMACEUTICALS
6.6 INC
6.7 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.8 MALLINCKRODT PHARMACEUTICALS
6.9 BIODELIVERY SCIENCES INTERNATIONAL INC.
6.10 VIATRIS INC.
6.11 HIKMA PHARMACEUTICALS PLC
6.12 CAMURUS AB
6.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
6.14 AMNEAL PHARMACEUTICALS LLC.
6.15 PURDUE PHARMA LP
6.16 ALVOGEN
6.17 FARAN SHIMI PHARMACEUTICAL
6.18 NOVARTIS AG
6.19 EMPLICURE AB
6.20 MODASA PHARMACEUTICALS PVT. LTD.
Chapter 7: Global Opioid Use Disorder Market By Region
7.1 Overview
7.2. North America Opioid Use Disorder Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Buprenorphine
7.2.4.2 Methadone
7.2.4.3 Naltrexone
7.2.4.4 and Others
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oral and Parenteral
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Opioid Use Disorder Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Buprenorphine
7.3.4.2 Methadone
7.3.4.3 Naltrexone
7.3.4.4 and Others
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oral and Parenteral
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Opioid Use Disorder Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Buprenorphine
7.4.4.2 Methadone
7.4.4.3 Naltrexone
7.4.4.4 and Others
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oral and Parenteral
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Opioid Use Disorder Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Buprenorphine
7.5.4.2 Methadone
7.5.4.3 Naltrexone
7.5.4.4 and Others
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oral and Parenteral
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Opioid Use Disorder Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Buprenorphine
7.6.4.2 Methadone
7.6.4.3 Naltrexone
7.6.4.4 and Others
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oral and Parenteral
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Opioid Use Disorder Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Buprenorphine
7.7.4.2 Methadone
7.7.4.3 Naltrexone
7.7.4.4 and Others
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oral and Parenteral
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Opioid Use Disorder Scope:
|
Report Data
|
Opioid Use Disorder Market
|
|
Opioid Use Disorder Market Size in 2025
|
USD XX million
|
|
Opioid Use Disorder CAGR 2025 - 2032
|
XX%
|
|
Opioid Use Disorder Base Year
|
2024
|
|
Opioid Use Disorder Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc, Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Hikma Pharmaceuticals PLC, Camurus AB, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., Purdue Pharma LP, Alvogen, Faran Shimi Pharmaceutical, Novartis AG, Emplicure AB, MODASA Pharmaceuticals Pvt. Ltd..
|
|
Key Segments
|
By Type
Buprenorphine
Methadone
Naltrexone
and Others
By Applications
Oral and Parenteral
|
